Further to earlier communication dated November 13, 2019, intimating about amalgamation of Zydus Technologies with the Company, Cadila Healthcare has infromed that the Board of Directors at their meeting held today, have now approved the draft Scheme of Amalgamation for amalgamation of Zydus Technologies (ZTL), Alidac Pharmaceuticals (APL), Liva Pharmaceuticals (LPL) and Dialforhealth India (DHIL) with Cadila Healthcare (CHL). ZTL, APL, LPL and DHIL are the wholly owned subsidiaries of the Company. The amalgamation is subject to the necessary approvals/ sanctions, from the National Company Law Tribunal, Bench at Ahmedabad or such other competent authority and shareholders and creditors of CHL, ZTL, APL, LPL and DHIL, if appiicable. The details as required under regulation 30 of the SEBI Regulations read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 in the prescribed format with regard to draft scheme of amalgamation are enclosed.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1867.90 |
| Dr. Reddys Lab | 1280.85 |
| Cipla | 1306.10 |
| Zydus Lifesciences | 942.80 |
| Lupin | 2281.30 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: